Instil Bio, Inc - TIL Net earnings per one share for the last twelve months

Official company branding of Instil Bio Inc. (TIL)

Instil Bio, Inc. (TIL) is developing unique methods to combat resistant neoplasms, aspiring to become a monopolist in its niche. The company's revenue relies on the commercialization of innovative lymphocyte-based drugs for metastasis therapy. The market dynamics for EPS reflected in the price action are 66.00, while the ESG strategy focuses on the strict disposal of biohazardous waste in sterile laboratories.

instilbio.com (TIL) - Earnings per share for the last twelve months from 02/11/2024 to 11/14/2026

Instil Bio, Inc - analytical breakdowns and key metrics (TIL)

- market value and analyst target forecast:
Stock Quotes instilbio.com|TIL - Analyst Consensus Forecast
- issuer market value details:
Market Value Instil Bio Inc.|TIL - Total Company Value
- company book value details:
Net Assets per Single Share Instil Bio|TIL - Company Book Value|Market Value to Book Value Ratio instilbio.com|TIL - Cumulative Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Instil Bio, Inc.|TIL - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Instil Bio Inc|TIL - Company Aggregate Debts|Debts to Book Value Instil Bio Inc.|TIL - Company Long-Term Debt|Company Short-Term Indebtedness Instil Bio|Immediate Liquidity instilbio.com
- earnings and valuation multiples indicators:
TIL - Net Income|Expected Net Income Instil Bio, Inc.|TIL - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Instil Bio Inc.|TIL - PEG Multiple|Business Value to Operating Income Before Depreciation Instil Bio Inc.|TIL - Operating profit EBITDA|Net earnings per one share for the last twelve months Instil Bio|TIL - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months instilbio.com|TIL - Earnings growth in current year|Earnings growth forecast for next year Instil Bio, Inc.
- revenue and sales details:
TIL - Company Revenue|Company Expected Revenue instilbio.com|TIL - Market Cap to Revenue|Market Cap to Future Revenue Ratio Instil Bio Inc.
Fundamental company valuation:TIL, instilbio.com
Product sample of Instil Bio, Inc

The market values Instil Bio, Inc. (TIL) through the lens of a radical strategic shift toward oncology antibodies. This indicator measures the rate of change in net earnings per share over a rolling year, neutralizing the impact of one-time accounting adjustments. By analyzing the 12-month EPS growth trend, investors can distinguish random spikes from genuine business scaling. Amid the binary risks inherent to biotech, such a curve confirms the resilience of the operating model.

Competitor analysis

legendbiotech.com (LEGN) - Net earnings per share for the last 12 months|SANA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Autolus Therapeutics PLC (AUTL)|Earnings per share for the last twelve months Allogene Therapeutics Inc|Earnings per share for the last twelve months RNAC|Earnings per share for the last twelve months Cellectis S.A. (CLLS)|Earnings per share for the last twelve months CRBU (cariboubio.com)|Genenta Science - Net earnings per share for the last 12 months|Earnings per share for the trailing year IPSC|Jasper Bio - Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Senti Biosciences, Inc. (SNTI)|ADAP: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months CERo Therapeutics Holdings (CERO)|Earnings per share for the last twelve months Alaunos Therapeutics Inc.|Earnings per share for the last 12 months ACHL (Achilles Tx)|Net earnings per share (EPS TTM) CRGX|PSTX - Net earnings per one share for the last twelve months|2seventy bio, Inc. - Net earnings per share for the last 12 months|Earnings per share for the trailing year GRCL